Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Repatha (Evolocumab) for the Treatment of Heterozygous and Homozygous Familial Hypercholesterolemia

Drug (Brand / Generic)

Repatha (Evolocumab)

Company

Amgen

Therapy Class

PCSK9 (proprotein convertase subtilisin/kexin type) inhibitor

Current Indication

Heterozygous and Homozygous Familial Hypercholesterolemia

Market Sector

Genetic anti-cholesterol drugs

Development Status

Approved in the US
Expand

Go Top